Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
[EN] SUBSTITUTED TETRAHYDROQUINAZOLINE COMPOUNDS AS KRAS INHIBITORS<br/>[FR] COMPOSÉS DE TÉTRAHYDROQUINAZOLINE SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE KRAS
申请人:ACCUTAR BIOTECHNOLOGY INC
公开号:WO2021216770A1
公开(公告)日:2021-10-28
The present disclosure relates to novel compounds that inhibits KRAS G12C, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.